Search results
Results from the WOW.Com Content Network
In the older literature survival rates have been given as 35–50% for stage I–II and 0–15% for stage III and IV uterine papillary serous carcinoma, [4] More recently it was reported that forty-two percent of 138 patients were found disease-free at five years. [3]
Bone cancer (including joint cancer) 0.5 Skin cancer (excluding basal and squamous) 3.4 Breast cancer (non-in situ) 11.3 Uterine cancer (cervix uteri) 1.2 Uterine cancer (corpus uteri) 1.2 Uterine cancer (not otherwise specified) 1.4 Ovarian cancer: 3.8 Prostate cancer: 7.8 Bladder cancer: 4.4 Renal cancer (kidney and renal pelvis cancer) 3.7 ...
The five-year survival rate for endometrial adenocarcinoma following appropriate treatment is 80%. [85] More than 70% of women diagnosed have FIGO stage I cancer, which has the best prognosis. Stage III and especially Stage IV cancers has a worse prognosis, but these are relatively rare, occurring in only 13% of cases.
As with endometrial carcinomas, the prognosis is influenced by the grade and type of the adenocarcinoma, being poorest with serous differentiation. MMMTs are highly malignant; a stage I tumor has an expected five-year survival rate of 50%, while the overall five-year survival rate is less than 20%. [1] Staging of uterine MMMTs is as follows: [3]
The highest increases in incidence rates for endometrial cancer have been observed in African American and Asian women, who tend to present with more aggressive subtypes of endometrial cancer. [53] The overall racial disparity in survival from endometrial cancer between African Americans and whites is greater than in any other type of cancer ...
In the United States there has been an increase in the 5-year relative survival rate between people diagnosed with cancer in 1975-1977 (48.9%) and people diagnosed with cancer in 2007-2013 (69.2%); these figures coincide with a 20% decrease in cancer mortality from 1950 to 2014. [8]
Uterine cancer effects approximately 3.1% of females during their lifetime. [8] Uterine cancer resulted in 45,000 deaths worldwide in 1990, with this number increasing to 58,000 deaths in 2010. [21] North America and Northern Europe have the highest rates of uterine cancer.
Ovarian cancer incidence rates are low in East Asia [56] and highest in Europe, the United States, and Australia/New Zealand. [57] Since 1975, survival rates for ovarian cancer have steadily improved with a mean decrease of 51% by 2006 of risk of death from ovarian cancer for an advanced stage tumour. [58]